Group 1 - The company announced on September 26 that it will assess the impact of current industry policy changes on its operations [1] - The company will carefully evaluate risks related to construction projects and drug development initiatives [1] - The company plans to prudently advance the progress of its construction projects [1]

Core Viewpoint - Fu'an Pharmaceutical (300194) announced on September 26 that it will disclose all R&D projects entering the registration process in its periodic reports and will provide interim disclosures for significant progress [1] Group 1 - The company will disclose relevant investments and matters that need to be reported through designated media [1]

证券日报网讯福安药业（300194）9月26日发布公告，在公司回答调研者提问时表示，中期分红主要从 回报投资者考虑。 ...

证券日报网讯 福安药业9月26日发布公告，在公司回答调研者提问时表示，二级市场股票价格波动受多 重因素影响，从公司的角度来讲，将持续做好投资者关系管理，做好生产经营工作，不断改善经营业 绩，积极回报投资者。 （编辑 袁冠琳） ...

Core Viewpoint - Fu'an Pharmaceutical (300194) announced on September 26 that its intellectual property mainly includes trademarks, utility models, preparation methods, or crystal form patents, but it has not yet obtained valuable composition patents [1] Intellectual Property - The company holds various types of intellectual property, including trademarks and utility models [1] - The focus on preparation methods and crystal form patents indicates a strategic approach to innovation [1] - The absence of valuable composition patents suggests potential areas for future development and investment [1]

Core Viewpoint - The company aims to actively participate in national drug procurement while optimizing its product structure and enhancing its core competitiveness to maintain stable development in response to industry policy changes [1]. Group 1 - The company announced on September 26 that it will respond to industry policy changes [1]. - The company plans to actively engage in national drug procurement [1]. - The company is focused on market expansion and improving its product structure to increase risk resistance [1]. Group 2 - The company aims to enhance its core competitiveness [1]. - The company strives to achieve stable development amidst changing industry dynamics [1].

Core Viewpoint - The company held an investor relations event to address various concerns regarding its business layout and development plans, emphasizing its commitment to maximizing the value of its intellectual property and navigating ongoing legal challenges [1][3]. Group 1: Company Operations and Developments - The company is considering the production of Metformin based on market conditions, as it holds relevant production approvals [3]. - A lawsuit is ongoing regarding a $73 million acquisition of a U.S. company that failed to fulfill its repurchase commitment [3]. - The progress of the Yunojin project is being managed normally, with production timelines dependent on drug application progress [3]. - The company is evaluating risks associated with the construction of Fuxiang Bioengineering due to changes in industry policies [3]. Group 2: Financial and Market Information - As of September 20, the company had 39,180 shareholders [3]. - The company can participate in over 10 products for the 11th batch of centralized procurement and will disclose relevant information as required [3]. - The third-quarter performance will be disclosed according to regulations [3]. Group 3: Strategic Initiatives and Future Plans - The company aims to fulfill its social responsibilities and contribute to local GDP growth, having operated in Chongqing for 20 years [3]. - Cross-industry investments in semiconductor technology are deemed risky without suitable conditions and regulatory approvals [3]. - The company currently has no plans for the listing of Fumin Bank [3]. - Future development will focus on adapting to industry policy changes, participating in national drug procurement, and enhancing core competitiveness [3].

Group 1: Investor Relations Activities - The investor relations activity was a performance briefing held on September 25, 2025, via an online platform [2] - Key participants included the Secretary of the Board, Tang Qin, and the Chief Financial Officer, Yu Xuesong [2] Group 2: Key Investor Questions and Company Responses - The company emphasized the importance of intellectual property in wealth creation and plans to maximize its value [2] - Regarding the production of Metformin, the company holds relevant approvals and will decide based on market conditions [3] - The company acquired a U.S. firm for $73 million, and the ongoing litigation is complex, with efforts to expedite the process [3] - The company has 39,180 shareholders as of September 20 [3] - The company can participate in over 10 products for the 11th batch of centralized procurement [3] Group 3: Company Strategy and Future Plans - The company is cautious about project progress due to industry policy changes and will evaluate risks [3] - The company focuses on generic drugs and has no current plans to invest in innovative drugs or robotics [5] - Future development plans include participating in national drug procurement and optimizing product structure to enhance competitiveness [6] - The company will continue to manage investor relations and consider cash dividends as a way to return value to investors [6]

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 为进一步提高投资者关系管理水平，促进公司完善公司治理，助力上市公司 高质量发展，福安药业（集团）股份有限公司（以下简称"公司"）将参加由重 庆证监局指导、重庆上市公司协会联合深圳市全景网络有限公司举办的"重庆辖 区 2025 年投资者网上集体接待日暨半年度业绩说明会活动"。 本次活动将于 2025 年 9 月 25 日（星期四）15:00-17:00 通过线上交流形式 举行，投资者可以登录全景网投资者关系互动平台（http://rs.p5w.net）参与本次 活动。 届时，公司有关高级管理人员将参加本次活动，与投资者进行"一对多"形 式的在线交流，回答投资者的提问。欢迎广大投资者积极参与！ 证券代码：300194 证券简称：福安药业 公告编号：2025-036 福安药业（集团）股份有限公司 关于参加"重庆辖区 2025 年 投资者网上集体接待日暨半年度业绩说明会活动"的公告 福安药业（集团）股份有限公司 董事会 二〇二五年九月十九日 特此公告。 ...

证券日报网讯 9月17日晚间，福安药业发布2025年半年度权益分派实施公告称，2025年半年度权益分派 方案为每10股派发现金股利0.20元人民币（含税），股权登记日为2025年9月24日，除权除息日为2025 年9月25日。 （文章来源：证券日报） ...